Inqovi Approved for the Treatment of MDS

Inqovi® Now Approved for the Treatment of Myelodysplastic Syndromes by Dr. David Schoenbaechler, PharmD, BCOP, CSP Dr. Joseph Barone, PharmD, BCOP Inqovi is a combination of...

Tazverik Approved for New Indications

Tazverik (tazemetostat) indicated for the treatment of adults and pediatric patients aged 16 years and older for Both Epithelioid Sarcoma and Follicular Lymphoma

Onco360 Selected to Dispense Inrebic

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib)